NewEdge Advisors’s Avanos Medical AVNS Stock Holding History

NewEdge Advisors’s Portfolio AVNS Stock Details AVNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.21K	Sell	129 -38,875	-100%	-$910K	﹤0.01%	3828
2026 Q1	$546K	Sell	39,004 -9,994	-20%	-$135K	﹤0.01%	1915
2025 Q4	$550K	Buy	48,998 +48,865	+36,741%	+$559K	﹤0.01%	1899
2025 Q3	$1.54K	Hold	133	–	–	﹤0.01%	3826
2025 Q2	$1.63K	Sell	133 -22	-14%	-$277	﹤0.01%	3656
2025 Q1	$2.22K	Sell	155 -13	-8%	-$203	﹤0.01%	3486
2024 Q4	$2.67K	Hold	168	–	–	﹤0.01%	3396
2024 Q3	$4.04K	Hold	168	–	–	﹤0.01%	3217
2024 Q2	$3.35K	Hold	168	–	–	﹤0.01%	3207
2024 Q1	$3.35K	Sell	168 -8	-5%	-$155	﹤0.01%	3272
2023 Q4	$3.95K	Buy	176 +30	+21%	+$619	﹤0.01%	3188
2023 Q3	$2.95K	Hold	146	–	–	﹤0.01%	2955
2023 Q2	$3.73K	Hold	146	–	–	﹤0.01%	2903
2023 Q1	$4.34K	Sell	146 -9	-6%	-$261	﹤0.01%	2824
2022 Q4	$248	Buy	+155	New	+$3.79K	﹤0.01%	3273

Other funds holding AVNS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NAM

Nexpoint Asset Management Dallas, Texas $1.5B AUM 83.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TAL

TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

NewEdge Advisors's AVNS Position: Q2 2026 in Review

NewEdge Advisors reduced its Avanos Medical (AVNS) stake by 100% in Q2 2026, selling an estimated $910K and leaving 129 shares worth $3.21K. The position accounts for ﹤0.01% of the portfolio, ranked #3828.

NewEdge Advisors first reported a position in AVNS in Q4 2022 and has held it in 15 quarters since. The position peaked at $550K in Q4 2025. 286 funds tracked by Wall St. Rank hold AVNS as of Q2 2026.

NewEdge Advisors held 129 shares of Avanos Medical worth $3.21K as of Q2 2026.
NewEdge Advisors sold 38,875 Avanos Medical shares in Q2 2026, an estimated $910K.
Avanos Medical made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3828 holding.
NewEdge Advisors first reported a position in Avanos Medical in Q4 2022 and has held it in 15 quarters since.
NewEdge Advisors's Avanos Medical position peaked at $550K in Q4 2025.
286 funds tracked by Wall St. Rank held Avanos Medical as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.